# Contact TB-500 Order: Editorial Corrections and Citation Queries

> Contact TB-500 Order with editorial corrections, citation queries, or source suggestions for our research digest on TB-500 and thymosin beta-4. We do not provide medical advice or sell any product.

For editorial corrections, citation queries, and source suggestions about the TB-500 and thymosin beta-4 literature.

## Reach the editors

TB-500 Order is an editorial digest, and the most useful messages we receive are about the record: a citation that should be corrected, a study we missed, a place where the fragment-versus-protein distinction could be drawn more clearly, or a regulatory update worth checking against the FDA source. Use the form below to send a note.

We cannot answer requests for medical guidance, dosing, or sourcing. We do not provide consultations, we do not prescribe, and we do not sell or supply TB-500 or any other substance. For anything touching personal health, a licensed clinician is the right contact, not this site.

## What to include

If you are flagging a citation, the most helpful note includes the page, the claim, and the DOI, PMID, or URL you believe is correct. If you are suggesting a study, a link to the PubMed or journal record lets us evaluate it quickly. If you are flagging a regulatory update, a link to the FDA page or notice is what lets us check it against the source rather than against a secondary report. We read corrections carefully — keeping the digest accurate against the published literature is the entire point of the project.

## What we will not do

To be unambiguous: we will not recommend a dose, suggest a route of administration, point to a supplier, or advise on how to obtain TB-500. Those requests fall outside what an editorial digest is and outside what is appropriate for a substance with the regulatory and safety profile described elsewhere on this site. The form here is for the record — the studies, the citations, and the facts — not for sourcing or clinical guidance.

---

A luminous reading of the TB-500 record — the Ac-LKKTETQ fragment lit where the studies confirm it, the full-length thymosin beta-4 substitutions and the dark human-evidence gap left plainly visible, and the FDA 503A status read first; no clinic behind the aurora and nothing here ordered, dispensed, or sold.